Amgen Shrugs Off Bone Density Concerns Related to Obesity Candidate [Yahoo! Finance]
AMGEN PRESENTS NEW DATA ACROSS RARE INFLAMMATORY DISEASES AT ACR 2024 [Yahoo! Finance]
AMGEN PRESENTS NEW DATA ACROSS RARE INFLAMMATORY DISEASES AT ACR 2024
EXCLUSIVE: Adial Pharmaceuticals Reveals Topline Results From Pharmacokinetics Study Of AD04 For Alcohol Use Disorder [Yahoo! Finance]
Amgen Inc. (NASDAQ: AMGN) is now covered by analysts at Citigroup Inc.. They set a "neutral" rating and a $335.00 price target on the stock.